Clinical Trials Browser

Active not recruiting × INDUSTRY × Glioma × Clear all

Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioblastoma, Glioma, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neuroectodermal Tumors, Primitive, Neoplasms, Neuroepithelial, Gliosarcoma, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT05610891 2026-03-18

Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG

Phase 1 Active not recruiting

50 enrolled

CNS

Glioma

NCT05916313 2026-03-17

A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3

Phase 1 Active not recruiting

18 enrolled

CNS

Glioma

NCT07238322 2026-02-20

[18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes

Active not recruiting

400 enrolled

CNS

Brain Neoplasms, Glioma

NCT03975829 2026-02-13

Pediatric Long-Term Follow-up and Rollover Study

Phase 4 Active not recruiting

163 enrolled

CNSMyeloid

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Histiocytosis, Langerhans-Cell, Neuroblastoma, Neurofibromatosis 1, Oligodendroglioma, Ganglioglioma, Neurocytoma, Neurofibroma, Plexiform

NCT03030066 2026-02-04

Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas

Phase 1 Active not recruiting

47 enrolled

CNS

Glioma

NCT05094336 2026-01-30

MTAPESTRY 101

Phase 1/2 Active not recruiting

329 enrolled

CNSGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Glioma, Stomach Neoplasms

NCT02650401 2025-12-24

STARTRK-NG

Phase 1/2 Active not recruiting

69 enrolled 1 FDA

CNSEndocrineGenitourinaryHead & NeckSarcoma

Thyroid Cancer, Papillary, Brain Neoplasms, Glioma, Medulloblastoma, Neoplasm Metastasis, Wilms Tumor, Neuroblastoma, Recurrence, Salivary Gland Neoplasms, Sarcoma, Sarcoma, Ewing, Central Nervous System Neoplasms, Nephroma, Mesoblastic

NCT02381886 2025-11-10

A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations

Phase 1 Active not recruiting

166 enrolled

CNSGastrointestinalMyeloidOther hematologic neoplasm

Astrocytoma, Glioblastoma, Glioma, Leukemia, Myelodysplastic Syndromes, Oligodendroglioma, Leukemia, Myeloid, Acute, Cholangiocarcinoma

NCT05023551 2025-09-16

Study of DSP-0390 in Patients With Recurrent High-Grade Glioma

Phase EARLY_PHASE1 Active not recruiting

39 enrolled

CNS

Brain Neoplasms, Glioblastoma, Glioma

NCT05342883 2025-09-05

GESTALT

Phase 4 Active not recruiting

61 enrolled

CNS

Glioblastoma, Glioma, Neoplasms

NCT04521686 2025-06-27

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Phase 1 Active not recruiting

200 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryHead & NeckSarcoma

Breast Neoplasms, Chondrosarcoma, Colonic Neoplasms, Glioblastoma, Glioma, Melanoma, Prostatic Neoplasms, Thyroid Neoplasms, Central Nervous System Neoplasms, Cholangiocarcinoma

NCT01473485 2025-05-01

ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Brain Tumors

Phase NA Active not recruiting

10 enrolled

CNS

Brain Neoplasms, Glioma

NCT05664243 2025-05-01

A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma

Phase 1/2 Active not recruiting

4 enrolled

CNS

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms by Site, Central Nervous System Neoplasms

NCT04164901 2025-04-03

Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

Phase 3 Active not recruiting

331 enrolled 25 charts 1 FDA

CNS

Glioma

NCT04458272 2025-03-18

A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma

Phase 2 Active not recruiting

25 enrolled

CNS

Glioma

NCT05561374 2024-11-29

Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma

Phase 1 Active not recruiting

16 enrolled

CNS

Astrocytoma, Glioblastoma, Glioma, Oligodendroglioma

NCT03678883 2024-11-07

9-ING-41 in Patients with Advanced Cancers

Phase 2 Active not recruiting

350 enrolled

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT05969691 2023-08-08

Radiomics-Based Visualization and Quantitative Validation of IDH1 Heterogeneity in Gliomas

Phase NA Active not recruiting

18 enrolled

CNS

Glioma

NCT05656053 2023-03-17

Intraoperative Rapid Diagnosis of Glioma Based on Fusion of Magnetic Resonance and Ultrasound Imaging

Active not recruiting

30 enrolled

CNS

Glioma

Clinical Trials

CLOVER-2

Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG

A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3

[18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes

Pediatric Long-Term Follow-up and Rollover Study

Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas

MTAPESTRY 101

STARTRK-NG

A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations

Study of DSP-0390 in Patients With Recurrent High-Grade Glioma

GESTALT

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Brain Tumors

A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma

Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma

Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma

9-ING-41 in Patients with Advanced Cancers

Radiomics-Based Visualization and Quantitative Validation of IDH1 Heterogeneity in Gliomas

Intraoperative Rapid Diagnosis of Glioma Based on Fusion of Magnetic Resonance and Ultrasound Imaging